Trial · NCT07384624
Combining Latency Reversing Agents to Address the HIV Reservoir
NCT07384624, Phase 1, Phase 2, Not yet recruiting, Erasmus Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combining Latency Reversing Agents to Address the HIV Reservoir. Trials, record NCT07384624. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07384624
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combining Latency Reversing Agents to Address the HIV Reservoir
- NCT number
- NCT07384624
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Erasmus Medical Center
- Conditions
- HIV (Human Immunodeficiency Virus), HIV -1 Infection
- Interventions
- Pyrimethamine (PYR), Lenalidomide, Topiramate (drug)
- First posted
- 2026-02-03
- Last updated
- 2026-02-03
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase I primary outcome: Fold change in cell-associated HIV-RNA | At time points 6 and 24 hours after treatment, compared to baseline | The fold change in cell-associated HIV-RNA within and between the study arms |
| Primary | Phase II primary outcome: Log transformed HIV-DNA | At time point 4 weeks compared to baseline | The change in log transformed HIV-DNA within the treatment group. Measured using IPDA and SQuHIVLa |
| Secondary | Phase I & II: Clinical safety and tolerability of the LRA drug combination. | Phase I: 1 week Phase II: 5 weeks | The number and severity of clinical and biochemical adverse events assessed using Common Terminology Criteria for Adverse Events version 6 |
| Secondary | Phase I: Participant preference on the latency reversing agent (LRA) combinations. | At 0 hours, 24 hours and 7 days | Participant preference for LRA combinations, quantitatively assessed using a pill diary with Likert scales 1-5 (higher scores meaning better outcome) |
| Secondary | Phase I: Participant quality of life during combination LRA treatment | Baseline, and at timepoint 7 days | To evaluate qualitative patient reported outcomes of quality of life assessed by semi-structured interviews |
| Secondary | Phase I: Plasma HIV-RNA kinetics during interventional treatment | At time points 6 hours, 24 hours and 7 days compared to baseline | Change in plasma HIV-RNA between and within arms |
| Secondary | Phase I: Change of the functionality of immune cells | At 7 days, compared to baseline | The change of the functionality of innate and adaptive immune cell subpopulations, specifically total T cells and HIV specific CD4+ and CD8+ T cells as well as HIV specific antibody profiles, between and within the groups |
| Secondary | Phase I: Change of the phenotype of immune cells | At 7 days, compared to baseline | The change of the phenotype of innate and adaptive immune cell subpopulations, specifically total T cells and HIV specific CD4+ and CD8+ T cells as well as HIV specific antibody profiles, between and within the groups |
| Secondary | Phase I: Pharmacokinetics of LRA compounds | At time points 2 hours, 6 hours, 24 hours and 7 days compared to baseline | Plasmaconcentrations Cmax will be measured using validated methods and related to the primary endpoint |
| Secondary | Phase I: Pharmacokinetics of LRA compounds | At time points 2 hours, 6 hours, 24 hours and 7 days compared to baseline | Plasmaconcentrations Cthrough will be measured using validated methods and related to the primary endpoint |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07384624
GET https://conductscience.org/api/trials/v1/NCT07384624/registered?page=2